Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

701 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Caswell-Jin JL, et al. Among authors: tripathy d. Nat Commun. 2019 Feb 8;10(1):657. doi: 10.1038/s41467-019-08593-4. Nat Commun. 2019. PMID: 30737380 Free PMC article.
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Vogel CL, et al. Among authors: tripathy d. J Clin Oncol. 2002 Feb 1;20(3):719-26. doi: 10.1200/JCO.2002.20.3.719. J Clin Oncol. 2002. PMID: 11821453 Corrected and republished. Clinical Trial.
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.
Chimge NO, Little GH, Baniwal SK, Adisetiyo H, Xie Y, Zhang T, O'Laughlin A, Liu ZY, Ulrich P, Martin A, Mhawech-Fauceglia P, Ellis MJ, Tripathy D, Groshen S, Liang C, Li Z, Schones DE, Frenkel B. Chimge NO, et al. Among authors: tripathy d. Nat Commun. 2016 Feb 26;7:10751. doi: 10.1038/ncomms10751. Nat Commun. 2016. PMID: 26916619 Free PMC article.
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab.
Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R. Dzimitrowicz H, et al. Among authors: tripathy d. J Clin Oncol. 2016 Oct 10;34(29):3511-3517. doi: 10.1200/JCO.2016.67.3624. J Clin Oncol. 2016. PMID: 27298406 Free PMC article.
701 results